Aisling Capital Management LP
NEW YORK NY · SEC CIK 0001766721
$4.72亿2026Q2 申报市值
14持仓数
99.0%前十大占比 · 第一大 72.5%
1 / 0新建仓 / 清仓
26Q126Q2
前十大持仓 占组合比例
2026Q2 买入最多 按季末市值估算
VTV THERAPEUTICS 新建仓+$188.25万
2026Q2 卖出最多 按季末市值估算
BBIO 减仓-$3,724.00万
2026Q2 持仓明细 点表头排序
导出 CSV 🔒| 代码 | 名称 | 市值 ▼ | 占比 | 股数 | 变动股数 | 变动 | 估算买卖额 | 操作 |
|---|---|---|---|---|---|---|---|---|
| BBIO | BRIDGEBIO PHARMA INC | $3.42亿 | 72.48% | 4,589,611 | -500,000 | -9.8% | -$3,724.00万 | 减仓 |
| GLUE | MONTE ROSA THERAPEUTICS INC | $3,764.71万 | 7.98% | 1,555,664 | 0 | 0.0% | — | 不变 |
| SNDX | SYNDAX PHARMACEUTICALS INC | $2,878.54万 | 6.10% | 1,316,806 | 0 | 0.0% | — | 不变 |
| CMPS | COMPASS PATHWAYS PLC | $2,026.76万 | 4.30% | 1,432,336 | 0 | 0.0% | — | 不变 |
| BCAX | BICARA THERAPEUTICS INC | $1,689.12万 | 3.58% | 568,919 | 0 | 0.0% | — | 不变 |
| BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $775.73万 | 1.64% | 1,018,018 | 0 | 0.0% | — | 不变 |
| SRRK | SCHOLAR ROCK HLDG CORP | $423.67万 | 0.90% | 77,031 | 0 | 0.0% | — | 不变 |
| URGN | UROGEN PHARMA LTD | $397.44万 | 0.84% | 108,000 | 0 | 0.0% | — | 不变 |
| — | BIOMEA FUSION INC | $301.17万 | 0.64% | 2,048,757 | 0 | 0.0% | — | 不变 |
| ACRS | ACLARIS THERAPEUTICS INC | $229.83万 | 0.49% | 434,455 | 0 | 0.0% | — | 不变 |
| EPRX | EUPRAXIA PHARMACEUTICALS INC | $214.82万 | 0.46% | 325,000 | 0 | 0.0% | — | 不变 |
| — | VTV THERAPEUTICS INC | $188.25万 | 0.40% | 50,000 | 50,000 | — | $188.25万 | 新建仓 |
| — | MARKER THERAPEUTICS INC | $47.83万 | 0.10% | 325,370 | 0 | 0.0% | — | 不变 |
| OKUR | ONKURE THERAPEUTICS INC | $40.40万 | 0.09% | 88,607 | 0 | 0.0% | — | 不变 |